Financial Comparison: Sigyn Therapeutics (OTCMKTS:SIGY) and Avinger (NASDAQ:AVGR)

Sigyn Therapeutics (OTCMKTS:SIGY) and Avinger (NASDAQ:AVGR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of current ratings and target prices for Sigyn Therapeutics and Avinger, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sigyn Therapeutics	0	0	0	0	N/A
Avinger	0	0	1	0	3.00

Avinger has a consensus price target of $5.00, indicating a potential upside of 16.69%. Given Avinger’s higher probable upside, analysts plainly believe Avinger is more favorable than Sigyn Therapeutics.

Risk and Volatility

Sigyn Therapeutics has a beta of -1.68, meaning that its share price is 268% less volatile than the S&P 500. Comparatively, Avinger has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Profitability

This table compares Sigyn Therapeutics and Avinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sigyn Therapeutics	N/A	N/A	-958.06%
Avinger	-239.41%	N/A	-106.16%

Insider & Institutional Ownership

10.0% of Sigyn Therapeutics shares are held by institutional investors. Comparatively, 18.3% of Avinger shares are held by institutional investors. 78.5% of Sigyn Therapeutics shares are held by insiders. Comparatively, 4.3% of Avinger shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Sigyn Therapeutics and Avinger’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sigyn Therapeutics	N/A	N/A	-$4.15 million	($3.60)	-1.67
Avinger	$7.65 million	0.89	-$18.32 million	($26.34)	-0.16

Sigyn Therapeutics has higher earnings, but lower revenue than Avinger. Sigyn Therapeutics is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.

Summary

Avinger beats Sigyn Therapeutics on 7 of the 11 factors compared between the two stocks.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

About Avinger

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.